NEW YORK, Dec. 1, 2025 /PRNewswire/ — This month, EP YAYING, the acclaimed Chinese high-end fashion house, celebrates the third anniversary of its boutique at the American Dream Mall in New Jersey. Since its debut in December 2022, the brand has captivated the international fashion scene by masterfully uniting Eastern aesthetics with contemporary design, delivering collections that are as elegant as they are wearable. Renowned for its impeccable craftsmanship and premium materials, EP YAYING has steadily built a devoted following among discerning American clients.

Designed by French architect Franklin Azzi, the boutique embodies a theme of “Dialogue and Balance.” Within a clean, minimalist space, subtle elements such as natural jade and inspirations drawn from traditional Chinese embroidery create a serene and sophisticated atmosphere—bridging heritage and modernity with quiet confidence. As the only high-end Chinese fashion brand in The Avenue luxury wing of American Dream Mall, EP YAYING stands proudly among global icons such as Hermès and Louis Vuitton, enriching the retail landscape with a unique cultural perspective.

Throughout the past three years, EP YAYING has deepened its relationship with U.S. customers through curated private events and personalized services. A longtime client, who has worn the brand for over two decades, remarked, “From business meetings to holiday celebrations, EP YAYING has been with me during life’s most meaningful moments. I admire the exquisite fabrics and craftsmanship—but even more, the graceful flow of each design connects me to a rich cultural heritage, offering a sense of refined individuality.” This profound emotional resonance has become central to the brand’s identity and sustained growth overseas.

Looking forward, EP YAYING remains committed to global expansion under the guiding principles of “Balance, Love, and Happiness.” Future collections will continue to showcase rare materials sourced from China—including Alxa cashmere and plateau yak wool—along with artisanal patterns from its premium Blue Label line. These elements bring the quiet power and grace of Eastern aesthetics to the global stage, offering a unique proposition for sophisticated international consumers who value cultural depth, exceptional quality, and a distinct point of view.

SHANGHAI, Dec. 1, 2025 /PRNewswire/ — MaxsMaking Inc. (Nasdaq: MAMK) (“MaxsMaking” or the “Company”), a manufacturer of customized consumer goods with a focus on advanced technology and innovation, addresses the ten-day Order of Suspension of Trading in the securities of the Company entered by the Securities and Exchange Commission (“SEC”) that expires tonight, December 1, 2025 at 11:59 PM Eastern Standard Time.

On November 14, 2025, the SEC entered the Order because of what appeared to the SEC to be the potential manipulation of the Company’s securities designed to artificially inflate the price and trading volume of the Company’s securities. The trading suspension did not relate to questions regarding the accuracy and adequacy of information in the marketplace about the Company. Moreover, the Company has no information to suggest that the trading involved any shares held by current MaxsMaking officers, directors, or employees. Similarly, the Company has no information at this time to suggest that the recent trading activity was conducted by persons known to current management.

The Company has pledged to and is cooperating fully with the SEC’s inquiry into the trading of the Company’s securities. The Company also is cooperating fully with related inquiries by other capital markets regulators, including responding to a request from Nasdaq Regulation for additional information. The Company stands fully behind the accuracy and content of all press releases that the Company has issued and its public filings, including its published financial statements.

The Company has not, does not and will not communicate with publishers of internet newsletters or internet chat boards. Moreover, the Company has not paid anyone and does not pay anyone to promote its securities. The Company’s retention of investor relations firms is solely for the purpose of ensuring prompt dissemination of material and financial information as required by regulators and establishing public awareness of corporate developments warranting disclosure. MaxsMaking refers all potential investors to warnings issued by the SEC about potentially misleading conduct in the promotion of stocks via the internet. Consistent with investor notices published by the SEC, MaxsMaking cautions potential investors who are interested in information about the Company to consider only information issued directly by the Company in filings with the SEC and press releases published by the Company.

In response and to advise the Company in connection with the trading suspension and the Company’s cooperation with regulators, the Company has hired Jacob Frenkel, Chair, Government Investigations and Securities Enforcement Practice, Dickinson Wright PLLC, to advise the Company. Mr. Frenkel, nationally recognized for defending and litigating trading suspensions, previously worked for the SEC’s Division of Enforcement, was a U.S. federal criminal prosecutor of public corruption and federal securities laws violations, and in his private practice has successfully litigated a trading suspension of an issuer’s securities such that the SEC set aside the trading suspension. Mr. Frenkel and Dickinson Wright PLLC will supplement and complement the efforts of Ellenoff Grossman & Schole LLP, which has represented and continues to represent the Company since its initial public offering.

Mr. Xiaozhong Lin, Chairman and Chief Executive Officer of MaxsMaking, remarked: “As I stated previously, we are proud of our successful Nasdaq IPO in July 2025. We are committed to continuing to build value for our shareholders. We do not condone improper trading activity in our securities, and we are pleased to have added an expert to our team to reassure securities regulators about our commitment to compliance with securities laws and regulations. We will support all legal efforts to pursue aggressively any persons who seek to harm the Company’s shareholders or impact artificially the value of the Company’s securities.”

The Company expressly disclaims any obligation in the future to address in public announcements or otherwise unusual patterns of trading in its securities or unusual prices or price swings thereof.

About MaxsMaking Inc.

Founded in 2007 and headquartered in Shanghai, MaxsMaking Inc. specializes in customized consumer goods with a focus on advanced technology and innovation. With production facilities in China’s Zhejiang and Henan provinces, the Company integrates digital production, software development, product design, brand management, online sales and international trade to deliver small-batch textile customization services. Its products include backpacks, shopping bags, aprons, and other promotional items. Using sustainable materials and proprietary order management technologies, MaxsMaking delivers high-quality, cost-effective products while emphasizing environmental protection and social responsibility. For more information, please visit the Company’s website: https://ir.maxsmaking.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

MaxsMaking Inc.
Investor Relations
Email: ir@maxsmaking.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

LISHUI, China, Dec. 1, 2025 /PRNewswire/ — CN Energy Group. Inc. (“CNEY” or the “Company”) (NASDAQ: CNEY), a Nasdaq-listed company, today announced that its wholly owned subsidiary, PATHENBOT Group Inc. (“PATHENBOT”), has launched its robotics solutions platform and its official website (www.pathenbot.com). This launch represents the next step in the development of PATHENBOT’s intelligent robotics initiatives.

The North American intelligent automation market continues to see increased demand. PATHENBOT’s mission is to provide customizable intelligent robotics products and related automation services to small and medium-sized industrial, logistics, and catering businesses in North America. PATHENBOT intends to integrate robotics, software, and artificial intelligence technologies to provide automation solutions as part of the Company’s continued development.

Wenhua Liu, CEO of CNEY, commented: “We are pleased to announce the launch of PATHENBOT’s robotics solutions platform and official website, which reflect our continued efforts to advance the Company’s strategic initiatives and support our broader growth plans.“

About CN Energy Group. Inc.

CN Energy Group. Inc. is currently listed on NASDAQ under the symbol “CNEY.” With patented proprietary bioengineering and physiochemical technologies, CNEY has pioneered and specialized in producing high-quality recyclable activated carbon and renewable energy from abandoned forest and agricultural residues, converting harmful wastes into invaluable wealth and delivering significant financial, economic, environmental and ecologic benefits. CNEY’s products and services have been widely used by food and beverage producers, industrial and pharmaceutical manufacturers, as well as environmental protection enterprises. For more information, please visit the Company’s website at www.cneny.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our registration statements and annual reports under the heading “Risk Factors” as filed with the Securities and Exchange Commission. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events or otherwise.

Information contained on, or that can be accessed through, the Company’s website or any other website or any social media is expressly not incorporated by reference into and is not a part of this press release.

HONG KONG, Dec. 1, 2025 /PRNewswire/ — Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group“, stock code: 0950.HK) expresses its deep condolences to the victims of the serious fire at Wang Fuk Court in Tai Po, which caused multiple casualties and left many residents homeless and in urgent need of assistance. The Group has made a donation of HK$200,000 to the “Support Fund for Wang Fuk Court in Tai Po” established by the HKSAR Government to render assistance to residents of Wang Fuk Court and support all relevant works.

As a pharmaceutical company listed in Hong Kong for over two decades, Lee’s Pharm deeply mourns the victims of the fire and extends heartfelt sympathy to those injured and the families affected. During this difficult time, the Group stands in solidarity with the people of Hong Kong, committing to support those impacted through concrete actions. We also call on all sectors of society to join hands in helping the victims overcome this hardship and rebuild confidence in their lives.

The Group also pays the highest tribute to the firefighters, medical staff, and volunteers who have worked tirelessly and bravely in the rescue efforts and expresses profound gratitude for their selfless dedication and perseverance.

About Lee’s Pharmaceutical Holdings Limited

Lee’s Pharm is a research-driven and market-oriented biopharmaceutical company with over 30 years of operation in the pharmaceutical industry in China. The company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales, and marketing based in Mainland China with global perspectives. Lee’s Pharm has established extensive partnerships with around 30 international companies and currently markets over 25 proprietary, generic, and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau, and Taiwan. The company focuses on several key disease therapeutic areas such as cardiovascular health, woman’s health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. For more information about Lee’s Pharm, please visit: www.leespharm.com.